Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

FULC

Fulcrum Therapeutics Inc

Dec 08 • 12:58PM ET

14.23

+5.33 59.87 %

Healthcare • Biotechnology • USA • NASD

Today, 6:31 AMPositive Phase 1b trial results for pociredir in sickle cell disease triggered the premarket surge.

Peers: VRTX IONS BLUE NBIX SRPT ULTA CRSP EDIT NTLA SGMO

| Held by: VTI IWM VXF IWN VTWO SCHA PINK DFAS AVSC VFMO

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-1.18	Insider Own	11.30%	Shs Outstand	54.11M	Perf Week	44.16%
Market Cap	770.03M	Forward P/E	-	EPS next Y	-1.24	Insider Trans	-0.24%	Shs Float	48.00M	Perf Month	86.00%
Enterprise Value	576.39M	PEG	-	EPS next Q	-0.31	Inst Own	89.92%	Short Float	7.43%	Perf Quarter	96.53%
Income	-71.11M	P/S	-	EPS this Y	-633.75%	Inst Trans	-2.39%	Short Ratio	5.35	Perf Half Y	99.84%
Sales	0.00M	P/B	3.88	EPS next Y	-5.71%	ROA	-28.80%	Short Interest	3.56M	Perf YTD	202.74%
Book/sh	3.67	P/C	3.84	EPS next 5Y	-	ROE	-31.21%	52W High	12.19 16.73%	Perf Year	305.38%
Cash/sh	3.71	P/FCF	-	EPS past 3/5Y	59.06% 54.59%	ROIC	-35.03%	52W Low	2.32 514.63%	Perf 3Y	112.37%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	61.02% -	Gross Margin	-	Volatility	11.77% 9.11%	Perf 5Y	17.30%
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	-305.92%	Oper. Margin	-	ATR (14)	1.30	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	17.70	Sales Y/Y TTM	-100.00%	Profit Margin	-	RSI (14)	71.52	Recom	1.56
Dividend Gr. 3/5Y	- -	Current Ratio	17.70	EPS Q/Q	9.95%	SMA20	42.17%	Beta	3.21	Target Price	17.44
Payout	-	Debt/Eq	0.04	Sales Q/Q	-	SMA50	50.90%	Rel Volume	46.32	Prev Close	8.90
Employees	45	LT Debt/Eq	0.02	Earnings	Oct 29 BMO	SMA200	113.86%	Avg Volume	666.11K	Price	14.23
IPO	Jul 18, 2019	Option/Short	Yes / Yes	EPS/Sales Surpr.	-5.51% -	Trades		Volume	17,176,441	Change	59.87%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-24-25	Initiated	Truist	Buy
Jul-29-25	Upgrade	H.C. Wainwright	Neutral → Buy	$4 → $12
May-23-25	Upgrade	Leerink Partners	Market Perform → Outperform	$12
May-15-25	Upgrade	Cantor Fitzgerald	Neutral → Overweight	$10
Sep-13-24	Downgrade	H.C. Wainwright	Buy → Neutral	$17 → $4
Sep-12-24	Downgrade	Stifel	Buy → Hold
Sep-12-24	Downgrade	RBC Capital Mkts	Outperform → Sector Perform	$15 → $4
Sep-12-24	Downgrade	Leerink Partners	Outperform → Market Perform	$4
Sep-12-24	Downgrade	Cantor Fitzgerald	Overweight → Neutral
Sep-12-24	Downgrade	BofA Securities	Neutral → Underperform	$10 → $2
Sep-09-24	Upgrade	BofA Securities	Underperform → Neutral	$5 → $10
May-20-24	Initiated	Cantor Fitzgerald	Overweight	$23
Mar-13-24	Initiated	RBC Capital Mkts	Outperform	$14
Sep-25-23	Initiated	Goldman	Neutral	$5
Aug-23-23	Upgrade	H.C. Wainwright	Neutral → Buy	$5 → $14
Aug-22-23	Upgrade	Stifel	Hold → Buy	$4 → $11
May-04-23	Downgrade	Goldman	Buy → Neutral	$9 → $3
Mar-10-23	Downgrade	H.C. Wainwright	Buy → Neutral	$20 → $6
Mar-10-23	Downgrade	Credit Suisse	Outperform → Neutral	$11 → $8
Mar-09-23	Downgrade	Stifel	Buy → Hold	$35 → $6

Show Previous Ratings

Dec-06-25 05:30PM	Fulcrum Therapeutics Announces Positive Initial Results from the 20 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease at the 67th American Society of Hematology Annual Meeting (GlobeNewswire)
Dec-05-25 04:30PM	Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +59.87%
Dec-02-25 08:30AM	Fulcrum Therapeutics to Host Investor Event to Review New Clinical Data from the PIONEER trial of Pociredir in Sickle Cell Disease on December 7, 2025 (GlobeNewswire) -9.32%
Nov-20-25 12:33PM	AGIO Stock Hits 52-Week Low on Mixed Sickle Cell Disease Study Results (Zacks)
Nov-19-25 04:20PM	Why Agios Plummeted, Losing Half Its Value, While Fulcrum Surged (Investor's Business Daily) +18.29%
04:30PM	Loading…
Nov-07-25 04:30PM	Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Nov-06-25 09:45AM	Caterpillar upgraded, Elf Beauty downgraded: Wall Street's top analyst calls (The Fly)
Nov-03-25 04:45PM	Fulcrum Therapeutics to Present New Clinical Data from the PIONEER trial of Pociredir in Sickle Cell Disease at the 67th American Society of Hematology Annual Meeting (GlobeNewswire) -7.21%
Oct-29-25 07:00AM	Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Third Quarter 2025 (GlobeNewswire) -6.40%
Oct-22-25 08:54AM	Fulcrum Therapeutics to Host Third Quarter 2025 Financial Results Conference Call and Webcast on Wednesday, October 29, 2025, at 8:00 a.m. ET (GlobeNewswire) -6.80%
Oct-14-25 07:00AM	Fulcrum Therapeutics to Present Preclinical Data for EED Inhibitor FTX-6274 at European Society for Medical Oncology (ESMO) Congress 2025 (GlobeNewswire)
Oct-10-25 04:30PM	Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -6.55%
Sep-12-25 04:30PM	Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Aug-26-25 08:00AM	Fulcrum Therapeutics to Present at Upcoming Investor Meetings (GlobeNewswire)
Aug-08-25 04:30PM	Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
06:48AM	Loading…
Jul-29-25 06:48AM	Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Second Quarter 2025 (GlobeNewswire)
06:45AM	Fulcrum Therapeutics Announces Results from the 12 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease (GlobeNewswire)
Jul-28-25 04:01PM	Fulcrum Therapeutics to Present Results from the 12 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease (GlobeNewswire)
Jul-11-25 04:30PM	Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jun-06-25 04:30PM	Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
May-30-25 01:17AM	Fulcrum Therapeutics, Inc. (FULC): A Bull Case Theory (Insider Monkey)
May-29-25 04:10PM	Fulcrum Therapeutics to Present at Upcoming Medical Meetings (GlobeNewswire)
08:30AM	Fulcrum Therapeutics to Participate in the 46th Annual Goldman Sachs Global Healthcare Conference (GlobeNewswire)
May-09-25 04:30PM	Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +5.77%
May-08-25 04:05PM	Fulcrum Therapeutics to Participate in Upcoming May Conferences (GlobeNewswire) +6.71%
May-02-25 03:03AM	Fulcrum Therapeutics Inc (FULC) Q1 2025 Earnings Call Highlights: Strategic Cost Reductions and ... (GuruFocus.com) +28.31%
01:27AM	Q1 2025 Fulcrum Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
May-01-25 01:55PM	Fulcrum Therapeutics, Inc. (FULC) Q1 2025 Earnings Call Transcript (Seeking Alpha) +13.77%
07:00AM	Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for First Quarter 2025 (GlobeNewswire)
Apr-24-25 08:00AM	Fulcrum Therapeutics to Host First Quarter 2025 Financial Results Conference Call and Webcast on Thursday, May 1, 2025, at 8:00 a.m. ET (GlobeNewswire)
04:30PM	Loading…
Apr-11-25 04:30PM	Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +8.55%
Mar-26-25 10:17AM	The Risk/Reward Of Avidity Biosciences And Its 2 Promising Programs (SeekingAlpha)
Mar-04-25 04:05PM	Fulcrum Therapeutics to Participate in the Leerink Partners Global Healthcare Conference (GlobeNewswire)
Feb-26-25 02:04AM	Fulcrum Therapeutics Inc (FULC) Q4 2024 Earnings Call Highlights: Strategic Advances Amid ... (GuruFocus.com) -10.27%
01:28AM	Q4 2024 Fulcrum Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
Feb-25-25 07:00AM	Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Fourth Quarter and Full Year 2024 (GlobeNewswire)
01:52AM	Earnings To Watch: Fulcrum Therapeutics Inc (FULC) Reports Q4 2024 Result (GuruFocus.com)
Feb-18-25 04:05PM	Fulcrum Therapeutics to Host Fourth Quarter and Full Year 2024 Financial Results Conference Call and Webcast on Tuesday, February 25, 2025, at 8:00 a.m. ET (GlobeNewswire)
Feb-07-25 04:30PM	Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Feb-06-25 04:05PM	Fulcrum Therapeutics to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference (GlobeNewswire)
Nov-28-24 12:00PM	Fulcrum Therapeutics (FULC) Upgraded to Buy: Here's Why (Zacks)
Nov-26-24 04:05PM	Fulcrum Therapeutics to Participate in Upcoming December Conferences (GlobeNewswire) +11.27%
Nov-14-24 02:07AM	Fulcrum Therapeutics Inc (FULC) Q3 2024 Earnings Call Highlights: Strategic Advancements Amidst ... (GuruFocus.com) -6.74%
Nov-13-24 07:00AM	Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Third Quarter 2024 (GlobeNewswire)
Nov-12-24 04:05PM	Fulcrum Therapeutics to Participate in the Stifel Healthcare Conference (GlobeNewswire)
Nov-06-24 08:00AM	Fulcrum Therapeutics to Host Third Quarter 2024 Financial Results Conference Call and Webcast on Wednesday, November 13, 2024 at 8:00 a.m. ET (GlobeNewswire)
Oct-18-24 08:00AM	Avidity Biosciences, Up 441%, Nears Another Record High As Dystrophy Space Heats Up (Investor's Business Daily)
Oct-11-24 04:30PM	Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +6.42%
Oct-09-24 03:30PM	Fulcrum Therapeutics Inc (FULC) Q2 2024 Earnings Call Highlights: Strong Financial Performance ... (GuruFocus.com)
Oct-07-24 03:02PM	FMR LLC's Strategic Reduction in Fulcrum Therapeutics Inc Shares (GuruFocus.com) -6.54%
Oct-04-24 09:35AM	Down -57.53% in 4 Weeks, Here's Why Fulcrum Therapeutics (FULC) Looks Ripe for a Turnaround (Zacks)
Sep-17-24 01:30AM	RA Capital Management's Strategic Acquisition of Fulcrum Therapeutics Shares (GuruFocus.com) +9.75%
Sep-16-24 09:35AM	Fulcrum Therapeutics (FULC) Loses -65.58% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks)
Sep-13-24 04:30PM	Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -7.56%
Sep-12-24 11:32AM	Fulcrum Therapeutics Suspends Rare Muscular Disease Candidate After Disappointing Data From Pivotal Trial (Benzinga) -61.13%
08:10AM	Fulcrum shares collapse as Sanofi-partnered muscular dystrophy drug fails key test (BioPharma Dive)
06:55AM	Fulcrum Therapeutics Announces Topline Results from Phase 3 REACH Clinical Trial of Losmapimod in Facioscapulohumeral Muscular Dystrophy (FSHD) (GlobeNewswire)
Sep-09-24 02:28PM	Fulcrum Therapeutics Upgraded: BofA Debates Pivotal Study Success For Losmapimod In Rare Genetic Muscle Disease (Benzinga)
Aug-27-24 04:05PM	Fulcrum Therapeutics to Participate in Upcoming September Conferences (GlobeNewswire) -9.09%
Aug-23-24 04:30PM	Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +6.22%
Aug-21-24 09:55AM	Wall Street Analysts Believe Fulcrum Therapeutics (FULC) Could Rally 71.02%: Here's is How to Trade (Zacks)
Aug-19-24 07:00AM	Fulcrum Therapeutics Strengthens Leadership Team with the Appointments of Isabel Kalofonos as Chief Commercial Officer and Heather Faulds as Chief Regulatory Affairs & Quality Assurance Officer (GlobeNewswire)
Aug-09-24 04:30PM	Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Aug-05-24 12:00PM	Fulcrum Therapeutics (FULC) Upgraded to Strong Buy: Here's What You Should Know (Zacks) -11.41%
12:00PM	Fulcrum Therapeutics, Inc. (FULC) Is Up 7.55% in One Week: What You Should Know (Zacks)
09:55AM	Does Fulcrum Therapeutics (FULC) Have the Potential to Rally 68.69% as Wall Street Analysts Expect? (Zacks)
Jul-31-24 07:00AM	Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Second Quarter 2024 (GlobeNewswire) +10.34%
Jul-24-24 08:00AM	Fulcrum Therapeutics to Host Second Quarter 2024 Financial Results Conference Call and Webcast on Wednesday, July 31, 2024, at 8:00 a.m. ET (GlobeNewswire)
Jun-12-24 08:00AM	Fulcrum Therapeutics to Present at the 31st Annual FSHD Society International Research Congress (GlobeNewswire)
Jun-06-24 08:00AM	Fulcrum Therapeutics to Participate in the Goldman Sachs' 45th Annual Global Healthcare Conference (GlobeNewswire)
May-26-24 09:02AM	Goldman Sachs Predicts up to 108% Rally for These 2 Strong Buy Stocks (TipRanks)
May-20-24 07:55AM	Cantor Fitzgerald Initiates Fulcrum Therapeutics at Overweight Rating With $23 Price Target (MT Newswires)
May-15-24 09:55AM	Wall Street Analysts See a 69.15% Upside in Fulcrum Therapeutics (FULC): Can the Stock Really Move This High? (Zacks)
May-14-24 08:55AM	Oppenheimer Cuts Fulcrum Therapeutics Price Target to $14 From $16, Maintains Outperform Rating (MT Newswires) +7.62%
07:49AM	Goldman Sachs Upgrades Fulcrum Therapeutics to Buy From Neutral, Price Target is $15 (MT Newswires)
03:01AM	Fulcrum Therapeutics Inc (FULC) Q1 2024 Earnings Call Transcript Highlights: Strategic ... (GuruFocus.com)
May-13-24 11:53AM	FULC Stock Earnings: Fulcrum Therapeutics Beats EPS for Q1 2024 (InvestorPlace)
11:02AM	Sanofi strikes $1bn deal with Fulcrum for muscular dystrophy drug (Pharmaceutical Technology)
08:45AM	Fulcrum Therapeutics, Sanofi Sign Licensing Deal for Facioscapulohumeral Muscular Dystrophy Treatment (MT Newswires)
08:32AM	Fulcrum Therapeutics Q1 2024 Earnings: Misses Analyst Net Income Projections Amid Strategic ... (GuruFocus.com)
07:47AM	Sanofi gambles $80M on Fulcrums muscular dystrophy drug (BioPharma Dive)
07:23AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday (InvestorPlace)
07:00AM	Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for First Quarter 2024 (GlobeNewswire)
06:00AM	Fulcrum Therapeutics Enters into a Collaboration and License Agreement with Sanofi for the Development and Commercialization of Losmapimod in Facioscapulohumeral Muscular Dystrophy (GlobeNewswire)
May-09-24 08:00AM	Fulcrum Therapeutics to Participate in Upcoming May Conferences (GlobeNewswire)
May-08-24 08:00AM	Fulcrum Therapeutics Announces Publication of Results from Phase 2b Clinical Trial of Losmapimod in Facioscapulohumeral muscular dystrophy (ReDUX4) in The Lancet Neurology (GlobeNewswire)
May-06-24 08:00AM	Fulcrum Therapeutics to Host First Quarter 2024 Financial Results Conference Call and Webcast on Monday, May 13, 2024, at 8:00 a.m. ET (GlobeNewswire)
Mar-28-24 04:05PM	Fulcrum Therapeutics to Participate at the Cantor Virtual Muscular Dystrophy Symposium (GlobeNewswire)
Mar-22-24 04:30PM	Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Mar-18-24 07:00AM	Fulcrum Therapeutics Appoints Patrick Horn M.D., Ph.D., as Chief Medical Officer (GlobeNewswire) -10.92%
Mar-08-24 04:30PM	Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Mar-05-24 08:00AM	Fulcrum Therapeutics to Participate at the Leerink Partners Global Biopharma Conference (GlobeNewswire)
Feb-28-24 09:35AM	Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Q4 2023 Earnings Call Transcript (Insider Monkey)
Feb-27-24 09:23PM	Q4 2023 Fulcrum Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
08:10AM	Fulcrum Therapeutics, Inc. (FULC) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
07:35AM	Fulcrum Therapeutics Inc (FULC) Reports Financial Results for Q4 and Full Year 2023 (GuruFocus.com)
07:00AM	Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Fourth Quarter and Full Year 2023 (GlobeNewswire)
Feb-20-24 04:01PM	Fulcrum Therapeutics to Host Fourth Quarter and Full Year 2023 Financial Results Conference Call and Webcast on Tuesday, February 27, 2024, at 8:00 a.m. ET (GlobeNewswire)
Feb-06-24 08:00AM	Fulcrum Therapeutics to Participate at the Oppenheimer 34th Annual Healthcare Life Sciences Conference (GlobeNewswire)
Dec-07-23 04:30PM	Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +7.13%

Fulcrum Therapeutics, Inc. is a clinical stage biopharmaceutical company, which develops new medicines and focuses on unlocking gene control mechanisms to develop small molecule therapies. Its product candidate includes Losmapimod and FTX-HbF. The company was founded by Michael R. Green, Danny Reinberg, Rudolf Jaenisch, Jeannie T. Lee, and Bradley E. Bernstein on August 18, 2015, and is headquartered in Cambridge, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Gould Robert J	Director	Nov 19 '25	Sale	11.03	15,000	165,495	484,864	Nov 21 04:15 PM
ROBERT J GOULD	Director	Nov 19 '25	Proposed Sale	9.73	45,000	437,850		Nov 19 04:20 PM
Tourangeau Greg	Principal Accounting Officer	May 08 '25	Sale	5.06	498	2,520	14,062	May 09 04:15 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

FULC

Fulcrum Therapeutics Inc

Upgrade your FINVIZ experience